Fig. 1.
Kaplan-–Meier plot of progression-free survival for patients with different CD8+CD28− subset status. The median progression-free survival (PFS) in patients with an increased CD8+CD28− subset percentage (≥24.0 %) was significantly lower than that in patients with a normal CD8+CD28− subset percentage (<24.0 %). (3.0 ± 0.3 vs. 5.0 ± 0.5 months, P < 0.001)